BD Diagnostics and Diagenode, a developer of infectious disease diagnostic products, have introduced their Diagenode Respiratory FLU A/B assay in Europe.
The CE-marked FLU A/B primers and probes kit will run on the BD MAX system, a fully automated molecular testing system designed for use in laboratories.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BD Diagnostics diagnostic systems product planning vice president Gregory Meehan said; "As the first partner assay validated for use on the BD MAX system, the launch of the Diagenode Respiratory FLU A/B kit demonstrates the flexibility and versatility of the BD MAX system and open system reagents in facilitating the rapid development of molecular testing assays."
Diagenode CEO Didier Allaer said the product is the first of several assays the company is planning to launch for the BD MAX system.
"What is unique about the BD MAX system versus other platforms is the ability to leverage the open system capability of the instrument throughout the validation process," Allaer said.
BD, in collaboration with Diagenode, is planning to expand the molecular testing menu by offering clinically relevant, IVD assays across various disease syndromes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition to infectious disease diagnostic products, Diagenode provides customer with a complete solution for epigenetics research.
Other assays available for BD MAX include a test for MRSA, with other partners assays in development.
